Trial Profile

A Phase 2 study of AT-301 in COVID-2019-infections

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 26 Feb 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AT-301 Atossa Therapeutics (Primary)
Indications COVID 2019 infections
Focus Therapeutic Use

Most Recent Events

25 Feb 2021 According to an Atossa Therapeutics media release, company is preparing to conduct an additional pre-clinical study which is expected to start this quarter based on input received from the FDA on this program before initiating this trial.
20 Nov 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com